Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: November 22, 2014
Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.
Journal: Clinical case reports
Published: May 29, 2014
High-risk myeloma: when to transplant-or not.
Journal: Seminars in oncology
Published: February 26, 2014
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 03, 2012
Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.
Journal: Haematologica
Published: June 27, 2012
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.
Journal: Haematologica
Published: June 13, 2012
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Journal: Blood
Published: June 08, 2012
Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.
Journal: Leukemia
Published: April 18, 2012
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Journal: Haematologica
Published: March 16, 2012
Unilateral conjunctival AL kappa amyloidosis with trace evidence of systemic amyloidosis.
Journal: The American journal of case reports
Published: January 01, 2012
Last Updated: 09/26/2026